Literature DB >> 3514335

Insulin and C-peptide levels after oral and intravenous glucose. Contribution of enteroinsular axis to insulin secretion.

S M Hampton, L M Morgan, J A Tredger, R Cramb, V Marks.   

Abstract

Peripheral venous plasma insulin and C-peptide concentrations were measured in 10 healthy volunteers, given either 100 g glucose orally or sufficient intravenous (i.v.) glucose to produce similar glucose concentrations when measured in arterialized blood. The incremental areas under both the insulin and C-peptide curves were significantly increased after oral as compared with i.v. glucose administration by 229% and 138%, respectively. Arteriovenous plasma glucose differences were higher after oral glucose administration and were positively correlated with plasma insulin concentrations. Plasma gastric inhibitory polypeptide (GIP) and insulin concentrations were measured in seven healthy volunteers given oral glucose loads ranging from 25 to 200 g. Both the magnitude and duration of the GIP and insulin responses after oral glucose ingestion were dose dependent. These results suggest that the main cause of the increase in peripheral insulin levels after large oral carbohydrate loads is augmented insulin secretion rather than reduced hepatic extraction, indicating the possibility that an enteroinsular factor does exist, in accordance with the "incretin" concept. They also emphasize the need to document both arterial and venous glucose concentrations for the correct interpretation of experiments investigating glucose homeostasis.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3514335     DOI: 10.2337/diab.35.5.612

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  9 in total

1.  Glycemic thresholds for activation of glucose counterregulatory systems are higher than the threshold for symptoms.

Authors:  N S Schwartz; W E Clutter; S D Shah; P E Cryer
Journal:  J Clin Invest       Date:  1987-03       Impact factor: 14.808

2.  Blood glucose and plasma insulin responses to fat free milk and low-lactose fat free milk in healthy human volunteers.

Authors:  E Salminen; S L Karonen; S Salminen
Journal:  Z Ernahrungswiss       Date:  1987-03

3.  The effects of glucose-dependent insulinotropic polypeptide infused at physiological concentrations in normal subjects and type 2 (non-insulin-dependent) diabetic patients on glucose tolerance and B-cell secretion.

Authors:  I R Jones; D R Owens; A J Moody; S D Luzio; T Morris; T M Hayes
Journal:  Diabetologia       Date:  1987-09       Impact factor: 10.122

4.  Reduced insulin clearance contributes to the increased insulin levels after administration of glucagon-like peptide 1 in mice.

Authors:  B Ahrén; K Thomaseth; G Pacini
Journal:  Diabetologia       Date:  2005-08-23       Impact factor: 10.122

5.  Effect of the enteroinsular axis on both the A- and B-cell response to arginine after oral glucose in man.

Authors:  I Shimizu; M Hirota; C Ohboshi; A Mizuno; K Shima
Journal:  Diabetologia       Date:  1987-11       Impact factor: 10.122

6.  Postprandial oscillations of plasma glucose, insulin and C-peptide in man.

Authors:  C Simon; M Follenius; G Brandenberger
Journal:  Diabetologia       Date:  1987-10       Impact factor: 10.122

7.  Blood glucose and plasma insulin responses to fat-free milk and low-lactose fat-free milk in young type 1 diabetics.

Authors:  J Wright; V Marks; S Salminen
Journal:  Z Ernahrungswiss       Date:  1987-12

Review 8.  The role of incretins in glucose homeostasis and diabetes treatment.

Authors:  Wook Kim; Josephine M Egan
Journal:  Pharmacol Rev       Date:  2008-12-12       Impact factor: 25.468

9.  Preserved incretin effect in type 1 diabetic patients with end-stage nephropathy treated by combined heterotopic pancreas and kidney transplantation.

Authors:  M A Nauck; M Büsing; C Orskov; E G Siegel; J Talartschik; A Baartz; T Baartz; U T Hopt; H D Becker; W Creutzfeldt
Journal:  Acta Diabetol       Date:  1993       Impact factor: 4.280

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.